COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Effects of Red Ginseng on Liver Function

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03945123
Recruitment Status : Completed
First Posted : May 10, 2019
Last Update Posted : May 10, 2019
Information provided by (Responsible Party):
Ki Tae Suk, Chuncheon Sacred Heart Hospital

Brief Summary:
Korea Red Ginseng (KRG) has effect on liver function

Condition or disease Intervention/treatment Phase
Liver Dysfunction Dietary Supplement: Red ginseng Not Applicable

Detailed Description:
Korea Red Ginseng (KRG) has been known as a natural product with anti-inflammatory effect in liver disease. Gut microbiota plays an important roles in the pathophysiology of nonalcoholic statohepatitis (NASH). We evaluated the effect of KRG on the pathophysiology of NASH

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 94 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effect of Korea Red Ginseng on Non-alcoholic Fatty Liver Disease
Actual Study Start Date : January 1, 2018
Actual Primary Completion Date : December 31, 2018
Actual Study Completion Date : December 31, 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Ginseng

Arm Intervention/treatment
Experimental: Ginseng trial
compare experimental group to controlled group
Dietary Supplement: Red ginseng
Red ginseng tablet 120g
Other Name: Red ginseng tablet

Primary Outcome Measures :
  1. Liver enzyme [ Time Frame: 1year ]
    Decrease liver enzyme level

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   37 Years to 63 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • AST or ALT level > 50 IU/L

Exclusion Criteria:

  • Viral hepatitis
  • Alcoholic hepatitis
  • Autoimmune hepatitis
  • Pancreatitis
  • Hemochromatosis
  • Wilson's disease
  • Drug induced liver injury
  • Cancer

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03945123

Layout table for location information
Korea, Republic of
Chuncheon, Kangwon, Korea, Republic of
Sponsors and Collaborators
Chuncheon Sacred Heart Hospital
Layout table for investigator information
Study Chair: Ki Tae Suk, PhD.Md. Chuncheon Sacred Heart Hospital
Principal Investigator: Jun Seok, MD. Chuncheon Sacred Heart Hospital
Layout table for additonal information
Responsible Party: Ki Tae Suk, Proffesor, Chuncheon Sacred Heart Hospital Identifier: NCT03945123    
Other Study ID Numbers: RIVER
First Posted: May 10, 2019    Key Record Dates
Last Update Posted: May 10, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Not yet

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Ki Tae Suk, Chuncheon Sacred Heart Hospital:
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Diseases
Digestive System Diseases